• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications don't work for a majority of people who are depressed. The individual approach to treatment could be the answer.

Cue is a digital intervention platform that translates passively acquired normal smartphone sensor data into personalized micro-interventions designed to improve mental health. We looked at the best-fitting personal ML models for each individual, using Shapley values, in order to understand their feature predictors. The results revealed distinct characteristics that changed mood in a predictable manner over time.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet the majority of people with the condition receive treatment. To improve outcomes, healthcare professionals must be able to identify and treat patients who are the most likely to benefit from certain treatments.

The ability to tailor depression treatments is one way to do this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit the most from certain treatments. They use sensors on mobile phones as well as a voice assistant that incorporates artificial intelligence, and other digital tools. Two grants were awarded that total more than $10 million, they will employ these tools to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research conducted to the present has been focused on sociodemographic and clinical characteristics. These include demographic factors like age, sex and education, clinical characteristics such as the severity of symptoms and comorbidities and biological markers such as neuroimaging and genetic variation.

While many of these factors can be predicted by the information available in medical records, very few studies have used longitudinal data to explore predictors of mood in individuals. Few studies also consider the fact that moods can differ significantly between individuals. Therefore, it is important to develop methods which permit the identification and quantification of individual differences between mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to recognize patterns of behaviour and emotions that are unique to each individual.

In addition to these methods, the team also developed a machine-learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm blends the individual differences to produce an individual "digital genotype" for each participant.

This digital phenotype was correlated with CAT DI scores, a psychometrically validated severity scale for symptom severity. The correlation was low, however (Pearson r = 0,08, BH adjusted P-value 3.55 10 03) and varied widely between individuals.

Predictors of Symptoms

Depression is the most common cause of disability around the world1, but it is often misdiagnosed and untreated2. Depression disorders are usually not treated because of the stigma that surrounds them and the lack of effective treatments.

To assist in individualized treatment, it is crucial to identify the factors that predict symptoms. However, the current methods for predicting symptoms rely on clinical interview, which is not reliable and only detects a small number of features related to depression.2

Machine learning can improve the accuracy of the diagnosis and treatment of depression treatment centers near me - Going At this website - by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes are able to capture a variety of unique actions and behaviors that are difficult to document through interviews and permit high-resolution, continuous measurements.

The study enrolled University of California Los Angeles (UCLA) students experiencing mild to severe depression symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA private depression treatment Grand Challenge. Participants were sent online for assistance or medical care based on the severity of their depression. Patients who scored high on the CAT DI of 35 or 65 were assigned online support via an online peer coach, whereas those with a score of 75 patients were referred for psychotherapy in person.

Participants were asked a series of questions at the beginning of the study concerning their demographics and psychosocial characteristics. These included age, sex, education, work, and financial status; if they were partnered, divorced or single; their current suicidal thoughts, intentions or attempts; as well as the frequency with that they consumed alcohol. Participants also scored their level of depression symptom severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted every other week for the participants who received online support and once a week for those receiving in-person support.

Predictors of the Reaction to Treatment

Research is focused on individualized treatment for depression treatment plan cbt. Many studies are focused on finding predictors that can aid clinicians in identifying the most effective drugs to treat each patient. Particularly, pharmacogenetics can identify genetic variants that influence the way that the body processes antidepressants. This lets doctors choose the medications that will likely work best for each patient, reducing the amount of time and effort required for trials and errors, while eliminating any adverse effects.

Another approach that is promising is to build models for prediction using multiple data sources, such as clinical information and neural imaging data. These models can be used to determine which variables are most predictive of a particular outcome, such as whether a drug will help with symptoms or mood. These models can also be used to predict the response of a patient to a treatment they are currently receiving which allows doctors to maximize the effectiveness of current therapy.

A new type of research utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of multiple variables and increase predictive accuracy. These models have shown to be effective in forecasting treatment outcomes, such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry, and are likely to be the norm in future treatment.

In addition to ML-based prediction models research into the mechanisms behind depression is continuing. Recent research suggests that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that an individualized treatment for depression will depend on targeted therapies that restore normal functioning to these circuits.

One way to do this is through internet-delivered interventions that can provide a more individualized and personalized experience for patients. One study found that an internet-based program improved symptoms and improved quality life for MDD patients. Furthermore, a randomized controlled trial of a personalized approach to depression treatment showed an improvement in symptoms and fewer adverse effects in a large percentage of participants.

Predictors of side effects

A major challenge in personalized depression treatment is predicting which antidepressant medications will cause minimal or no side effects. Many patients take a trial-and-error approach, using various medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics provides a novel and exciting method of selecting antidepressant medicines that are more effective and specific.

There are many variables that can be used to determine the antidepressant that should be prescribed, including gene variations, patient phenotypes such as ethnicity or gender and co-morbidities. However it is difficult to determine the most reliable and accurate predictive factors for a specific treatment is likely to require randomized controlled trials with considerably larger samples than those typically enrolled in clinical trials. This is because it could be more difficult to determine moderators or interactions in trials that only include one episode per participant instead of multiple episodes spread over a period of time.

Additionally the estimation of a patient's response to a particular medication will likely also require information on symptoms and comorbidities as well as the patient's previous experience of its tolerability and effectiveness. Presently, only a handful of easily assessable sociodemographic and clinical variables appear to be correlated with the severity of MDD factors, including gender, age race/ethnicity BMI, the presence of alexithymia and the severity of depression symptoms.

The application of pharmacogenetics in treatment for depression is in its beginning stages and there are many hurdles to overcome. First, it is essential to be able to comprehend and understand the definition of the genetic mechanisms that cause depression, and an accurate definition of an accurate predictor of treatment response. Ethics like privacy, and the responsible use of genetic information should also be considered. In the long term pharmacogenetics can offer a chance to lessen the stigma that surrounds mental health care and improve treatment outcomes for those struggling with alternative depression treatment options. Like any other psychiatric treatment it is essential to carefully consider and implement the plan. At present, it's ideal to offer patients an array of depression medications that are effective and encourage them to talk openly with their doctors.